Return to Search
EN
Hairy cell leukemia is diagnosed through a comprehensive evaluation process. This process includes medical history review, physical examination, blood tests, bone marrow examinations, and molecular tests.
Medical History: Detailed information is gathered about the patient's general health, previous illnesses, past treatments, and current symptoms.
Physical Examination: The doctor evaluates the general physical condition and specifically checks for enlargement of organs such as lymph nodes, spleen, and liver. These findings can provide clues about the disease's spread.
Complete Blood Count (CBC): A blood sample is analyzed for the number of red blood cells (erythrocytes), white blood cells (leukocytes), and platelets, as well as hemoglobin levels and hematocrit. In hairy cell leukemia, leukopenia (low white blood cell count), anemia (low red blood cell count), and thrombocytopenia (low platelet count) are typically observed.
Blood Biochemistry Tests: Various blood biochemistry tests are performed to assess organ function and general metabolic status. Abnormal values may indicate the disease's effects on organs or other co-existing health issues.
Peripheral Blood Smear: A peripheral blood smear is a critical test for diagnosing hairy cell leukemia. In this test, a blood sample is examined under a microscope for abnormal white blood cells (leukocytes). In hairy cell leukemia, specific leukemia cells called 'hairy cells' are observed, which have characteristic cytoplasmic projections. This examination helps doctors observe abnormal cells and reach a diagnosis. A peripheral blood smear is usually evaluated in conjunction with other tests for a more precise diagnosis and to determine appropriate treatment methods.
Bone Marrow Aspiration and Biopsy: Bone marrow aspiration and biopsy is a fundamental step for diagnosing hairy cell leukemia. In this procedure, bone marrow samples are taken, usually from the hip bone (pelvis), using a special needle. Liquid bone marrow is obtained via aspiration, and a solid tissue sample via biopsy. These samples are meticulously examined under a microscope by hematologists and pathologists. In hairy cell leukemia, the presence and spread of 'hairy cells' and the condition of normal blood cells are evaluated in bone marrow samples. Since bone marrow fibrosis associated with hairy cell leukemia often leads to insufficient aspiration samples ('dry tap'), biopsy is particularly important in this situation.
Cytogenetic Analysis: Cytogenetic analysis is performed to detect chromosomal abnormalities in blood and/or bone marrow cells. This test can help understand the genetic characteristics of the disease.
Immunohistochemistry: Examines surface proteins and other markers on cells in bone marrow or biopsy samples to help identify cell types and their characteristic features.
Flow Cytometry: Flow cytometry is a laboratory test that plays a critical role in the diagnosis of hairy cell leukemia. This method analyzes specific characteristics of cells in blood or bone marrow samples, such as surface proteins and intracellular molecules. During the test, cells are labeled with fluorescent dyes and scanned with a light beam. This allows for the detection of the presence and quantity of markers specific to hairy cell leukemia, such as CD103, CD11c, and CD25. Flow cytometry significantly contributes to the accurate identification of the disease and the assessment of its spread.
Computed Tomography (CT) Scan: Used to create detailed cross-sectional images of the body's internal organs and tissues. It is particularly useful in evaluating findings indicative of disease spread, such as lymphadenopathy (enlarged lymph nodes), splenomegaly (enlarged spleen), and hepatomegaly (enlarged liver).
Gene Mutation Test: Blood or bone marrow samples are analyzed in the laboratory to detect the BRAF V600E gene mutation, which is found in approximately 80-90% of hairy cell leukemia patients. This mutation leads to uncontrolled growth of leukemia cells. The gene mutation test plays a critical role in confirming the diagnosis and determining targeted treatment options, which helps optimize patients' treatment response.
How is Hairy Cell Leukemia Diagnosed?
Medical History: Detailed information is gathered about the patient's general health, previous illnesses, past treatments, and current symptoms.
Physical Examination: The doctor evaluates the general physical condition and specifically checks for enlargement of organs such as lymph nodes, spleen, and liver. These findings can provide clues about the disease's spread.
Complete Blood Count (CBC): A blood sample is analyzed for the number of red blood cells (erythrocytes), white blood cells (leukocytes), and platelets, as well as hemoglobin levels and hematocrit. In hairy cell leukemia, leukopenia (low white blood cell count), anemia (low red blood cell count), and thrombocytopenia (low platelet count) are typically observed.
Blood Biochemistry Tests: Various blood biochemistry tests are performed to assess organ function and general metabolic status. Abnormal values may indicate the disease's effects on organs or other co-existing health issues.
Peripheral Blood Smear: A peripheral blood smear is a critical test for diagnosing hairy cell leukemia. In this test, a blood sample is examined under a microscope for abnormal white blood cells (leukocytes). In hairy cell leukemia, specific leukemia cells called 'hairy cells' are observed, which have characteristic cytoplasmic projections. This examination helps doctors observe abnormal cells and reach a diagnosis. A peripheral blood smear is usually evaluated in conjunction with other tests for a more precise diagnosis and to determine appropriate treatment methods.
Bone Marrow Aspiration and Biopsy: Bone marrow aspiration and biopsy is a fundamental step for diagnosing hairy cell leukemia. In this procedure, bone marrow samples are taken, usually from the hip bone (pelvis), using a special needle. Liquid bone marrow is obtained via aspiration, and a solid tissue sample via biopsy. These samples are meticulously examined under a microscope by hematologists and pathologists. In hairy cell leukemia, the presence and spread of 'hairy cells' and the condition of normal blood cells are evaluated in bone marrow samples. Since bone marrow fibrosis associated with hairy cell leukemia often leads to insufficient aspiration samples ('dry tap'), biopsy is particularly important in this situation.
Cytogenetic Analysis: Cytogenetic analysis is performed to detect chromosomal abnormalities in blood and/or bone marrow cells. This test can help understand the genetic characteristics of the disease.
Immunohistochemistry: Examines surface proteins and other markers on cells in bone marrow or biopsy samples to help identify cell types and their characteristic features.
Flow Cytometry: Flow cytometry is a laboratory test that plays a critical role in the diagnosis of hairy cell leukemia. This method analyzes specific characteristics of cells in blood or bone marrow samples, such as surface proteins and intracellular molecules. During the test, cells are labeled with fluorescent dyes and scanned with a light beam. This allows for the detection of the presence and quantity of markers specific to hairy cell leukemia, such as CD103, CD11c, and CD25. Flow cytometry significantly contributes to the accurate identification of the disease and the assessment of its spread.
Computed Tomography (CT) Scan: Used to create detailed cross-sectional images of the body's internal organs and tissues. It is particularly useful in evaluating findings indicative of disease spread, such as lymphadenopathy (enlarged lymph nodes), splenomegaly (enlarged spleen), and hepatomegaly (enlarged liver).
Gene Mutation Test: Blood or bone marrow samples are analyzed in the laboratory to detect the BRAF V600E gene mutation, which is found in approximately 80-90% of hairy cell leukemia patients. This mutation leads to uncontrolled growth of leukemia cells. The gene mutation test plays a critical role in confirming the diagnosis and determining targeted treatment options, which helps optimize patients' treatment response.